Impact of HAART advent on admission patterns and survival in HIV-infected patients admitted to an intensive care unit

被引:97
作者
Casalino, E
Wolff, M
Ravaud, P
Choquet, C
Bruneel, F
Regnier, B
机构
[1] Bichat Claude Bernard Univ Hosp, Infect Dis Intens Care Unit, Paris, France
[2] Bichat Claude Bernard Univ Hosp, Dept Epidemiol & Biostat, Paris, France
关键词
HIV; antiretroviral therapy; AIDS; intensive care; prognosis; survival; pneumonia; Pneumocystis carinii; sepsis; toxoplasma;
D O I
10.1097/01.aids.0000131301.55204.a7
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Several studies found increased survival times and decreased hospitalization rates since the introduction of highly active antiretroviral therapy (HAART). Objective: To examine the impact of HAART on admission patterns and survival of HIV-infected patients admitted to an intensive care unit (ICU). Design: Prospective observational cohort study. Setting and subjects: All HIV-infected patients admitted from 1 January 1995 to 30 June 1999, to an infectious diseases ICU located in Paris. Main outcome measures: ICU utilization and admission patterns, and survival. Results: A total of 426 HIV-related admissions were included. Sepsis increased from 16.3% to 22.6% from the pre- to the post-HAART era, whereas AIDS-related admissions decreased from 57.7% to 37% (P < 0.05). No significant difference in ICU utilization was found. In both periods, half of the patients were not on antiretroviral treatment at ICU admission. In-ICU mortality was 23%, without significant difference between the study periods. By multivariabie analysis, in-ICU mortality was significantly associated with SAPS II > 40, Omega score > 75 and mechanical ventilation; and long-term survival with admission in the HAARTera and AIDS at ICU admission. Cumulative survival rates after ICU discharge were 85.3% and 70.8% after 12 and 24 months, respectively. Conclusions: HAART had little impact on ICU utilization by HIV-infected patients. After the introduction of HAART AIDS-related conditions decreased and sepsis increased as reasons for ICU admission. Whereas ICU survival was dependent on usual prognostic markers, long-term survival was clearly dependent on HIV disease stage and HAART availability. In both study periods, at least a half of the HIV infected patients were not on anti-retroviral treatment at the time of ICU admission. © 2004 Lippincott Williams & Wilkins.
引用
收藏
页码:1429 / 1433
页数:5
相关论文
共 25 条
[1]   Clinical course, prognostic factors, and outcome prediction for HIV patients in the ICU - The PIP (Pulmonary complications, ICU support, and prognostic factors in hospitalized patients with HIV) study [J].
Afessa, B ;
Green, B .
CHEST, 2000, 118 (01) :138-145
[2]   EARLY PREDICTORS OF OUTCOME FOR HIV PATIENTS WITH NEUROLOGICAL FAILURE [J].
BEDOS, JP ;
CHASTANG, C ;
LUCET, JC ;
KALO, T ;
GACHOT, B ;
WOLFF, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (01) :35-40
[3]   Predictors of short- and long-term survival in HIV-infected patients admitted to the ICU [J].
Casalino, E ;
Mendoza-Sassi, G ;
Wolff, M ;
Bédos, JP ;
Gaudebout, C ;
Regnier, B ;
Vachon, F .
CHEST, 1998, 113 (02) :421-429
[4]   OUTCOME OF INTENSIVE-CARE IN PATIENTS WITH HIV-INFECTION [J].
DEPALO, VA ;
MILLSTEIN, BH ;
MAYO, PH ;
SALZMAN, SH ;
ROSEN, MJ .
CHEST, 1995, 107 (02) :506-510
[5]   Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration [J].
Detels, R ;
Muñoz, A ;
McFarlane, G ;
Kingsley, LA ;
Margolick, JB ;
Giorgi, J ;
Scharager, LD ;
Phair, JP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (17) :1497-1503
[6]   ICU admission in patients infected with the human immunodeficiency virus - a multicentre survey [J].
Gill, JK ;
Greene, L ;
Miller, R ;
Pozniak, A ;
Cartledge, J ;
Fisher, M ;
Nelson, MR ;
Soni, N .
ANAESTHESIA, 1999, 54 (08) :727-732
[7]   Assessing the benefits of antiretroviral therapy [J].
Gulick, RM .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (06) :471-473
[8]  
INFUSO A, 2000, BEH, P11
[9]  
JACOBSON MA, 1998, AIDS, P157
[10]  
Jones J L, 1999, MMWR CDC Surveill Summ, V48, P1